APO Research
Talk to an analyst

APO RESEARCH · REPORT

Antiviral Drugs for the Treatment of Hepatitis C (HCV)

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Outlook and Growth Opportunities 2026

27 December 2025193 pages

Choose your research edition.

Industry ResearchAntiviral Drugs for the Treatment of Hepatitis C (HCV) Industry Research Report 2026128 pages · $2,950 USDIndustry Growth & TrendsGlobal Antiviral Drugs for the Treatment of Hepatitis C (HCV) Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Antiviral Drugs for the Treatment of Hepatitis C (HCV) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Antiviral Drugs for the Treatment of Hepatitis C (HCV) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Antiviral Drugs for the Treatment of Hepatitis C (HCV) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Antiviral Drugs for the Treatment of Hepatitis C (HCV) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Antiviral Drugs for the Treatment of Hepatitis C (HCV) market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Antiviral Drugs for the Treatment of Hepatitis C (HCV) market include AbbVie, Asegua Therapeutics, Bristol Myers Squibb, Gilead Sciences, Merck, Ascletis Pharma, Cosunter pharmaceutical, Kawin Technology and Sanhome Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Antiviral Drugs for the Treatment of Hepatitis C (HCV) market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Antiviral Drugs for the Treatment of Hepatitis C (HCV) and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Antiviral Drugs for the Treatment of Hepatitis C (HCV) sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Antiviral Drugs for the Treatment of Hepatitis C (HCV) market size, projected growth trends, production technologies, key applications, and end-use industries.

Antiviral Drugs for the Treatment of Hepatitis C (HCV) Segment by Company

AbbVie

Asegua Therapeutics

Bristol Myers Squibb

Gilead Sciences

Merck

Ascletis Pharma

Cosunter pharmaceutical

Kawin Technology

Sanhome Pharmaceutical

Beijing Sihuan Pharmaceutical

YiChang HEC ChangJiang Pharmaceutical

Chia Tai Tianqing Pharmaceutical

Antiviral Drugs for the Treatment of Hepatitis C (HCV) Segment by Type

NS3/4A Protease Inhibitors

NS5A Inhibitors

NS5B Polymerase Inhibitors

Other

Antiviral Drugs for the Treatment of Hepatitis C (HCV) Segment by Application

Hospital and Clinic

Pharmacy

Other

Antiviral Drugs for the Treatment of Hepatitis C (HCV) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Antiviral Drugs for the Treatment of Hepatitis C (HCV) status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Antiviral Drugs for the Treatment of Hepatitis C (HCV) market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Antiviral Drugs for the Treatment of Hepatitis C (HCV) significant trends, drivers, influence factors in global and regions.

6. To analyze Antiviral Drugs for the Treatment of Hepatitis C (HCV) competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antiviral Drugs for the Treatment of Hepatitis C (HCV) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antiviral Drugs for the Treatment of Hepatitis C (HCV) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antiviral Drugs for the Treatment of Hepatitis C (HCV).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Antiviral Drugs for the Treatment of Hepatitis C (HCV) market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Antiviral Drugs for the Treatment of Hepatitis C (HCV) industry.

Chapter 3: Detailed analysis of Antiviral Drugs for the Treatment of Hepatitis C (HCV) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Antiviral Drugs for the Treatment of Hepatitis C (HCV) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Antiviral Drugs for the Treatment of Hepatitis C (HCV) in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Antiviral Drugs for the Treatment of Hepatitis C (HCV) Industry Trends Table 2. Antiviral Drugs for the Treatment of Hepatitis C (HCV) Industry Drivers Table 3. Antiviral Drugs for the Treatment of Hepatitis C (HCV) Industry Opportunities and Challenges Table 4. Antiviral Drugs for the Treatment of Hepatitis C (HCV) Industry Restraints Table 5. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue Share by Company (2021-2026) Table 7. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Volume Share by Company (2021-2026) Table 9. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Company Ranking, (2024-2026) & (USD Million) Table 11. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Key Company Manufacturing Base & Headquarters Table 12. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Company, Product Type & Application Table 13. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of NS3/4A Protease Inhibitors Table 18. Significant Companies of NS5A Inhibitors Table 19. Significant Companies of NS5B Polymerase Inhibitors Table 20. Significant Companies of Other Table 21. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Volume by Type (2021-2026) & (K Units) Table 23. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Volume by Type (2027-2032) & (K Units) Table 24. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Volume Share by Type (2021-2026) Table 25. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Volume Share by Type (2027-2032) Table 26. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Type (2021-2026) Table 30. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Hospital and Clinic Table 32. Significant Companies of Pharmacy Table 33. Significant Companies of Other Table 34. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Volume by Application (2021-2026) & (K Units) Table 36. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Volume by Application (2027-2032) & (K Units) Table 37. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Volume Share by Application (2021-2026) Table 38. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Volume Share by Application (2027-2032) Table 39. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Application (2021-2026) Table 43. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Application (2027-2032) Table 44. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Region (2021-2026) & (K Units) Table 46. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share by Region (2021-2026) Table 47. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Region (2027-2032) & (K Units) Table 48. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share by Region (2027-2032) Table 49. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Region (2021-2026) Table 52. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Region (2027-2032) Table 54. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Average Price (US$/Unit) by Region (2021-2026) Table 55. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Average Price (US$/Unit) by Region (2027-2032) Table 56. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Country (2021-2026) & (K Units) Table 59. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share by Country (2021-2026) Table 60. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Country (2027-2032) & (K Units) Table 61. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share by Country (2027-2032) Table 62. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Market Share by Country (2021-2026) Table 64. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Market Share by Country (2027-2032) Table 66. AbbVie Company Information Table 67. AbbVie Business Overview Table 68. AbbVie Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. AbbVie Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio Table 70. AbbVie Recent Development Table 71. Asegua Therapeutics Company Information Table 72. Asegua Therapeutics Business Overview Table 73. Asegua Therapeutics Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Asegua Therapeutics Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio Table 75. Asegua Therapeutics Recent Development Table 76. Bristol Myers Squibb Company Information Table 77. Bristol Myers Squibb Business Overview Table 78. Bristol Myers Squibb Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Bristol Myers Squibb Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio Table 80. Bristol Myers Squibb Recent Development Table 81. Gilead Sciences Company Information Table 82. Gilead Sciences Business Overview Table 83. Gilead Sciences Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Gilead Sciences Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio Table 85. Gilead Sciences Recent Development Table 86. Merck Company Information Table 87. Merck Business Overview Table 88. Merck Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Merck Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio Table 90. Merck Recent Development Table 91. Ascletis Pharma Company Information Table 92. Ascletis Pharma Business Overview Table 93. Ascletis Pharma Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Ascletis Pharma Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio Table 95. Ascletis Pharma Recent Development Table 96. Cosunter pharmaceutical Company Information Table 97. Cosunter pharmaceutical Business Overview Table 98. Cosunter pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Cosunter pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio Table 100. Cosunter pharmaceutical Recent Development Table 101. Kawin Technology Company Information Table 102. Kawin Technology Business Overview Table 103. Kawin Technology Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Kawin Technology Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio Table 105. Kawin Technology Recent Development Table 106. Sanhome Pharmaceutical Company Information Table 107. Sanhome Pharmaceutical Business Overview Table 108. Sanhome Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Sanhome Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio Table 110. Sanhome Pharmaceutical Recent Development Table 111. Beijing Sihuan Pharmaceutical Company Information Table 112. Beijing Sihuan Pharmaceutical Business Overview Table 113. Beijing Sihuan Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Beijing Sihuan Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio Table 115. Beijing Sihuan Pharmaceutical Recent Development Table 116. YiChang HEC ChangJiang Pharmaceutical Company Information Table 117. YiChang HEC ChangJiang Pharmaceutical Business Overview Table 118. YiChang HEC ChangJiang Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. YiChang HEC ChangJiang Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio Table 120. YiChang HEC ChangJiang Pharmaceutical Recent Development Table 121. Chia Tai Tianqing Pharmaceutical Company Information Table 122. Chia Tai Tianqing Pharmaceutical Business Overview Table 123. Chia Tai Tianqing Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. Chia Tai Tianqing Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio Table 125. Chia Tai Tianqing Pharmaceutical Recent Development Table 126. Key Raw Materials Table 127. Raw Materials Key Suppliers Table 128. Antiviral Drugs for the Treatment of Hepatitis C (HCV) Distributors List Table 129. Antiviral Drugs for the Treatment of Hepatitis C (HCV) Customers List Table 130. Research Programs/Design for This Report Table 131. Authors List of This Report Table 132. Secondary Sources Table 133. Primary Sources List of Figures Figure 1. Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Image Figure 2. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value (2021-2032) & (US$ Million) Figure 4. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales (2021-2032) & (K Units) Figure 5. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. NS3/4A Protease Inhibitors Image Figure 10. NS5A Inhibitors Image Figure 11. NS5B Polymerase Inhibitors Image Figure 12. Other Image Figure 13. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Volume Share by Type (2021-2032) Figure 16. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Type (2021-2032) Figure 19. Hospital and Clinic Image Figure 20. Pharmacy Image Figure 21. Other Image Figure 22. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Volume Share by Application (2021-2032) Figure 25. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Application (2021-2032) Figure 28. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 29. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value (2021-2032) & (US$ Million) Figure 33. North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value (2021-2032) & (US$ Million) Figure 39. South America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Antiviral Drugs for the Treatment of Hepatitis C (HCV) Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • NS3/4A Protease Inhibitors
  • NS5A Inhibitors
  • NS5B Polymerase Inhibitors
  • Other
Applications
  • Hospital and Clinic
  • Pharmacy
  • Other
Companies covered
  • AbbVie
  • Asegua Therapeutics
  • Bristol Myers Squibb
  • Gilead Sciences
  • Merck
  • Ascletis Pharma
  • Cosunter pharmaceutical
  • Kawin Technology
  • Sanhome Pharmaceutical
  • Beijing Sihuan Pharmaceutical
  • YiChang HEC ChangJiang Pharmaceutical
  • Chia Tai Tianqing Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value (2021-2032)
  4. 1.2.2 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Volume (2021-2032)
  5. 1.2.3 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Dynamics
  1. 2.1 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Industry Trends
  2. 2.2 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Industry Drivers
  3. 2.3 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Industry Opportunities and Challenges
  4. 2.4 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Industry Restraints
3 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market by Company
  1. 3.1 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Company Revenue Ranking in 2025
  2. 3.2 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Revenue by Company (2021-2026)
  3. 3.3 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Volume by Company (2021-2026)
  4. 3.4 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Average Price by Company (2021-2026)
  5. 3.5 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Company Ranking (2024-2026)
  6. 3.6 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Company Manufacturing Base and Headquarters
  7. 3.7 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Company Product Type and Application
  8. 3.8 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market by Type
  1. 4.1 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Type Introduction
  2. 4.1.1 NS3/4A Protease Inhibitors
  3. 4.1.2 NS5A Inhibitors
  4. 4.1.3 NS5B Polymerase Inhibitors
  5. 4.1.4 Other
  6. 4.2 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Volume by Type
  7. 4.2.1 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value by Type
  11. 4.3.1 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value by Type (2021-2032)
  13. 4.3.3 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Type (2021-2032)
5 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market by Application
  1. 5.1 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Application Introduction
  2. 5.1.1 Hospital and Clinic
  3. 5.1.2 Pharmacy
  4. 5.1.3 Other
  5. 5.2 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Volume by Application
  6. 5.2.1 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value by Application
  10. 5.3.1 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value by Application (2021-2032)
  12. 5.3.3 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Application (2021-2032)
6 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Regional Sales and Value Analysis
  1. 6.1 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Region (2021-2032)
  3. 6.2.1 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Region: 2021-2026
  4. 6.2.2 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Region (2027-2032)
  5. 6.3 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value by Region (2021-2032)
  7. 6.4.1 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value by Region: 2021-2026
  8. 6.4.2 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value by Region (2027-2032)
  9. 6.5 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value (2021-2032)
  12. 6.6.2 North America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value (2021-2032)
  15. 6.7.2 Europe Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value (2021-2032)
  21. 6.9.2 South America Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Country, 2025 VS 2032
7 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Country-level Sales and Value Analysis
  1. 7.1 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Country (2021-2032)
  4. 7.3.1 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Country (2021-2026)
  5. 7.3.2 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales by Country (2027-2032)
  6. 7.4 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value by Country (2021-2032)
  7. 7.4.1 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value by Country (2021-2026)
  8. 7.4.2 Global Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 AbbVie
  2. 8.1.1 AbbVie Company Information
  3. 8.1.2 AbbVie Business Overview
  4. 8.1.3 AbbVie Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 AbbVie Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio
  6. 8.1.5 AbbVie Recent Developments
  7. 8.2 Asegua Therapeutics
  8. 8.2.1 Asegua Therapeutics Company Information
  9. 8.2.2 Asegua Therapeutics Business Overview
  10. 8.2.3 Asegua Therapeutics Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Asegua Therapeutics Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio
  12. 8.2.5 Asegua Therapeutics Recent Developments
  13. 8.3 Bristol Myers Squibb
  14. 8.3.1 Bristol Myers Squibb Company Information
  15. 8.3.2 Bristol Myers Squibb Business Overview
  16. 8.3.3 Bristol Myers Squibb Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Bristol Myers Squibb Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio
  18. 8.3.5 Bristol Myers Squibb Recent Developments
  19. 8.4 Gilead Sciences
  20. 8.4.1 Gilead Sciences Company Information
  21. 8.4.2 Gilead Sciences Business Overview
  22. 8.4.3 Gilead Sciences Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Gilead Sciences Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio
  24. 8.4.5 Gilead Sciences Recent Developments
  25. 8.5 Merck
  26. 8.5.1 Merck Company Information
  27. 8.5.2 Merck Business Overview
  28. 8.5.3 Merck Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Merck Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio
  30. 8.5.5 Merck Recent Developments
  31. 8.6 Ascletis Pharma
  32. 8.6.1 Ascletis Pharma Company Information
  33. 8.6.2 Ascletis Pharma Business Overview
  34. 8.6.3 Ascletis Pharma Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Ascletis Pharma Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio
  36. 8.6.5 Ascletis Pharma Recent Developments
  37. 8.7 Cosunter pharmaceutical
  38. 8.7.1 Cosunter pharmaceutical Company Information
  39. 8.7.2 Cosunter pharmaceutical Business Overview
  40. 8.7.3 Cosunter pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Cosunter pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio
  42. 8.7.5 Cosunter pharmaceutical Recent Developments
  43. 8.8 Kawin Technology
  44. 8.8.1 Kawin Technology Company Information
  45. 8.8.2 Kawin Technology Business Overview
  46. 8.8.3 Kawin Technology Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Kawin Technology Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio
  48. 8.8.5 Kawin Technology Recent Developments
  49. 8.9 Sanhome Pharmaceutical
  50. 8.9.1 Sanhome Pharmaceutical Company Information
  51. 8.9.2 Sanhome Pharmaceutical Business Overview
  52. 8.9.3 Sanhome Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Sanhome Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio
  54. 8.9.5 Sanhome Pharmaceutical Recent Developments
  55. 8.10 Beijing Sihuan Pharmaceutical
  56. 8.10.1 Beijing Sihuan Pharmaceutical Company Information
  57. 8.10.2 Beijing Sihuan Pharmaceutical Business Overview
  58. 8.10.3 Beijing Sihuan Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Beijing Sihuan Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio
  60. 8.10.5 Beijing Sihuan Pharmaceutical Recent Developments
  61. 8.11 YiChang HEC ChangJiang Pharmaceutical
  62. 8.11.1 YiChang HEC ChangJiang Pharmaceutical Company Information
  63. 8.11.2 YiChang HEC ChangJiang Pharmaceutical Business Overview
  64. 8.11.3 YiChang HEC ChangJiang Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 YiChang HEC ChangJiang Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio
  66. 8.11.5 YiChang HEC ChangJiang Pharmaceutical Recent Developments
  67. 8.12 Chia Tai Tianqing Pharmaceutical
  68. 8.12.1 Chia Tai Tianqing Pharmaceutical Company Information
  69. 8.12.2 Chia Tai Tianqing Pharmaceutical Business Overview
  70. 8.12.3 Chia Tai Tianqing Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Chia Tai Tianqing Pharmaceutical Antiviral Drugs for the Treatment of Hepatitis C (HCV) Product Portfolio
  72. 8.12.5 Chia Tai Tianqing Pharmaceutical Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Value Chain Analysis
  2. 9.1.1 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Mode & Process
  6. 9.2 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Distributors
  9. 9.2.3 Antiviral Drugs for the Treatment of Hepatitis C (HCV) Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst